1. Home
  2. KXIN vs CVKD Comparison

KXIN vs CVKD Comparison

Compare KXIN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$1.45

Market Cap

1.7M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$1.13

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
CVKD
Founded
2015
2022
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
4.0M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
KXIN
CVKD
Price
$1.45
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $13.00
AVG Volume (30 Days)
★ 3.5M
1.2M
Earning Date
11-26-2019
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 23.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.11
$1.00
52 Week High
$22.00
$14.64

Technical Indicators

Market Signals
Indicator
KXIN
CVKD
Relative Strength Index (RSI) 33.27 37.57
Support Level $0.42 $1.00
Resistance Level $2.81 $2.17
Average True Range (ATR) 0.26 0.11
MACD 0.16 0.04
Stochastic Oscillator 25.85 36.62

Price Performance

Historical Comparison
KXIN
CVKD

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: